

F. No. 19(719)/2016/DP/NPPA/Div.II

भारत सरकार

Government of India

रसायन और उर्वरक मंत्रालय

Ministry of Chemicals & Fertilizers

औषध विभाग

Department of Pharmaceuticals

राष्ट्रीय औषध मूल्य निर्धारण प्राधिकरण

National Pharmaceutical Pricing Authority

तीसरी/पांचवी मंजिल 5th / 3rd Floor,
वाई.एम.सी.ए. सांस्कृतिक केन्द्र बिल्डिंग
YMCA Cultural Center Building,
1, जय सिंह रोड, नई दिल्ली-110001
1, Jai Singh Road, N. Delhi - 110001.
दिनांक :- 05.01.2017

OFFICE MEMORANDUM


Subject: 4th meeting of the Committee of Experts under DPCO, 2013 (Re-Scheduled).

In supersession of this office OM of even no dated 03.01.2017, it is stated that the fourth meeting of the committee of Experts constituted under para 11(3 & 4) of DPCO, 2013 is re-scheduled to be held on 24.01.2017 (Tuesday) at 11.30 AM in the conference room of National Pharmaceuticals Pricing Authority (NPPA), 3rd Floor, YMCA Cultural Center Building, 1, Jai Singh Road, New Delhi - 110001 to consider the cases as on date (Annexure) under the provision contained in Para 11 (3 & 4), which states that:

- (a) Notwithstanding anything contained in sub-paragraphs (1) and (2), in case of injections or inhalation or any other medicine for which dosage form or strength or both are not specified in the Schedule-I of the Drugs (Prices Control) Order, 2013, the Government may fix and notify separate ceiling price or retail price for such formulations with specific therapeutic rationale, considering the type of packaging or pack size or dosage compliance or content in the pack namely liquid, gaseous or any other form, in the unit dosage as the case may be, conforming to Indian Pharmacopoeia or other standards as specified in the Drugs and Cosmetics Act, 1940 (23 of 1940) and the rules made thereunder for the same formulation.
- (b) The Government shall form a Committee of Experts, as it may deem fit, within a period of fifteen days from the date of issue of this order, to recommend fixing of separate ceiling price of scheduled formulations or retail price of a new drug as per the above parameters.

2. Moreover, any other issue(s) relating to above mention subject, with the permission of Chair will also be taken up/discussed in the meeting.

3. You are, therefore, requested to make it convenient to attend the meeting.


(ए. के. खुराना)
निदेशक

Encl: As above.

To,

The Members of the Committee

Copy to:

1. PPS to Chairman, NPPA
2. PPS to MS, NPPA
3. PPS to Adviser (Cost), NPPA

F. No. 19(719)/2016/DP/NPPA/Div.II
भारत सरकार
Government of India
रसायन एवं उर्वरक मंत्रालय
Ministry of Chemical and Fertilizers
औषध विभाग
Department of Pharmaceuticals
राष्ट्रीय औषध मूल्य निर्धारण प्राधिकरण
National Pharmaceutical Pricing Authority

5th/3rd Floor,
YMCA cultural Centre Building
1, Jai Singh Road, N. Delhi- 11001
Dated 05.01.2017

OFFICE MEMORANDUM

Subject: Re-Constitution of Committee of Experts under Drugs (Prices Control) Order, 2013 to recommend fixation of separate ceiling/retail price of formulations which fall under the purview of Para 11(3&4) of DPCO 2013.

The undersigned is directed to refer to SO 1192(E) dated 22.3.2016, para 11(3 & 4) of DPCO 2013 and this office letter dated 6.4.2016 regarding the constitution of the Committee of Experts under Drugs (Prices Control) Order, 2013. With the approval of the Competent Authority, the Committee of Experts under Para 11(3&4) of DPCO 2013 has been re-constituted as under:

| | | |
|----|--|-------------|
| 1 | Adviser(cost), National Pharmaceutical Pricing Authority | Chairperson |
| 2 | Representative of Drug Controller General of India, Ministry of Health and Family Welfare, New Delhi | Member |
| 3 | The Head of Department of Cardiology, AIIMS, New Delhi or representative | Member |
| 4 | The Head of Department of Medicine, AIIMS, New Delhi or representative | Member |
| 5 | Prof. Y. K. Gupta, Head, Department of Pharmacology, AIIMS, New Delhi | Member |
| 6 | The Executive Director, National Health System Resource Centre or representative | Member |
| 7 | Dr. Sarita Dhawan, Add. Director, CGHS, New Delhi | Member |
| 8 | Shri D. P. Pathak, Director, Delhi Institute of Pharmaceutical Science and Research (DIPSAR) | Member |
| 9 | Director General, Indian Council of Medical Research or representative | Member |
| 10 | Any other subject specialist(s) / expert(s) co-opted by the committee on case to case basis | Member |
| 11 | Director (Pricing), NPPA | Convener |

2. Representation by concerned Ex.-officio members/institutions must ensure adequate seniority and expertise of the officers concerned for the required level of knowledge and responsibility.

3. The required quorum to conduct the meeting shall be Chairperson plus four other members (representatives) excluding the convener.

4. The Committee shall recommend fixing of separate ceiling price of scheduled formulations or retail price of a new drug as per the parameters mentioned under para 11(3&4) of DPCO 2013.

sd/-
(A.K. Khurana)
Director (Pricing)

To:
Members of the Committee
Copy to:
PPS to Chairman, NPPA,
PPS to Member Secretary, NPPA

Representation of companies under para 11(3)

05.01.2017

| Sr. No. | Company Name | Formulation | S.O No. | Dated | Recived on |
|---------|--------------|---|---------|------------|---------------------------|
| 1 | Cipla | Budesonide Inhalation 100mcg & 200mcg | 1561(E) | 27.4.2016 | 12.7.2016 & 25.11.2016 |
| 2 | Unimed | Pre- Filled Syringe and Glass Vial packs of Hydroxypropyl Methylcellulose injection 2% | 1561(E) | 27.4.2016 | 11.8.2016 |
| 3 | Aurolab | Hydroxypropyl Methylcellulose injection 2% | 1561(E) | 27.4.2016 | 30.8.2016 |
| 4 | Ipca | Metoclopramide Injection 2ml Ampoul and 10ml vial each containing 5mg/ml | | | |
| 5 | Wockhardt | Dicyclomine Injection | 3431(E) | 10.11.2016 | 24.11.2016 |
| 6 | Glenmark | Digihaler FB 100/200/400 and Budesonide/ Formoterol (100/6, 200/6 and 400/6mcg) | | | 15.12.2016 |
| 7 | Abbott | Tramadol injection 50mg/ml | | | |
| 8 | IDMA | Small Volume Parenterals | | | |